dave@davidgaus.com
We realize that many researchers would rather work with a big corporation than with a small outfit such as ours. But, since big corporations are subject to the law of organizational constraint, that often means that many worthwhile potential projects are, for them, taboo.
Organizational constraint in business often produces unfortunate results. One big corporation we’re familiar with, Baxter International could possibly benefit from trying to develop the alternate AIDS treatment mentioned above. However, our ideas about “heterotoxicity,” which are an important part of our research, can be used to criticize some of their products.
Click here to read about heterotoxicity.
Our impression is that Baxter's plasmapheresis technology is going to become less and less profitable for them because of considerations having to do with heterotoxicity. We have spelled that out for them in another presentation, and there has been some indication that they have taken us seriously. Our alternate treatment for AIDS, which would make use of plasmapheresis, could make up for what might be future Baxter losses.
We'd state in more detail what an alternate treatment for AIDS might be, but our experiences with big corporations haven't been good. If we were to convince Baxter of the feasibility of what we have in mind, they might carry it out, but they'd be unlikely to compensate us. It’s an unfortunate fact of life, but that’s the way that big corporations usually behave.
We feel that we've satisfied our obligation to society, at least for the time being, by posting this web presentation for free.
We'd be happy to try to do more in future, but Baxter or someone else would need to buy some of our stock or otherwise provide assured compensation.
Small companies like ours have the potential to develop new jobs for the U.S. economy precisely because they are less constrained. For big companies the game often isn’t major innovation but just lowering prices for existing technology by such means as consolidation or setting up manufacturing plants overseas. A smaller corporation, however, with technology that’s experimental, is more likely to spawn competitors than to consolidate, and it has to remain in the U.S. where it can maintain close ties with its research base.
So, if you are a researcher and willing to work with us, you might possibly be helping your country’s economy--which in our opinion is rather embattled.
However we do have one more point to make, not for our own commercial purposes, but in the interest of public health and social justice.
CONCLUSION OF ARTICLE